DISCO Pharmaceuticals secures $40 million upfront from AbbVie in a collaboration to develop AND-gated bispecific therapeutics for solid tumors, with up to $2.5 billion in potential milestone payments.
Written By: Kalyani Boharapi, M. Pharm (RA)
Reviewed By: Pharmacally Editorial Team
Cologne, Germany-based DISCO Pharmaceuticals has entered a strategic research collaboration and option-to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need. Announced on November 19, 2026, the agreement includes $40 million in upfront payments and up to $2.5 billion in potential milestones, alongside tiered royalties on worldwide net sales.
The collaboration combines DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach with AbbVie’s global oncology research and development capabilities. Together, the companies aim to identify highly selective therapeutics capable of targeting tumors while limiting damage to healthy tissues.
AND-Gated Targeting to Improve Tumor Selectivity
Bispecific therapeutics can bind two different molecular targets, creating opportunities to improve target recognition and therapeutic activity. However, targeting antigens that are also present in healthy tissues can limit treatment selectivity and increase the risk of off-tumor toxicity.
DISCO’s AND-gated approach addresses this challenge by identifying combinations of surface proteins that distinguish tumor cells from healthy tissues. Rather than relying on a single tumor-associated antigen, the approach uses two molecular targets as a combined recognition signal enabling preferential activity against tumor cells expressing both targets while sparing healthy cells expressing only one. The underlying DISCOtech® platform maps the cell-surface protein landscape (the surfaceome) to uncover these tumor-selective target pairs and potentially widen the therapeutic window.
AbbVie Gains Exclusive Licensing Options
Under the terms of the agreement, DISCO will lead specified research activities to identify and advance selected programs. Following successful completion of those activities, AbbVie will hold the option to exclusively license selected programs for further development.
In exchange, DISCO receives $40 million upfront and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales of commercialized products.
Strategic Significance and Development Outlook
“The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors,” said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals. “Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology.”
Ajla Hrle, Ph.D., Chief Business Officer of DISCO, added that the partnership further validates the company’s platform and complements its existing internal and partnered pipeline programs.
The immediate focus remains on early research and candidate identification prior to AbbVie’s licensing option window. No specific therapeutic candidates, solid tumor indications, or clinical trial timelines were disclosed. While the deal provides substantial commercial validation for DISCO’s surfaceome-based discovery engine, the clinical impact of its AND-gated candidates will ultimately depend on preclinical validation and subsequent clinical development.
Reference
DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors, DISCO Pharmaceuticals, 19 November 2026
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.
